INTRODUCTION {#sec1_1}
============

Although genus *Acinetobacter* was originally identified in the early 20th century, it was recognized as a ubiquitous pathogen only in the last decade ([@B1]). *Acinetobacter baumannii,* a member of the *Acinetobacter calcoaceticus---A. baumannii* complex, makes up to 73% of all *Acinetobacter* spp. and is the most commonly-involved pathogen in clinical infections ([@B2]). During the last decade, hospital-acquired infections involving multidrug-resistant *A.* *baumannii* isolates have been reported, often in association with contamination of hospital equipment or cross-contamination by colonized hands of personnel attending patients ([@B1]). Initial concern about multidrug-resistant and carbapenem-resistant *Acinetobacter baumannii* (CRAB)-associated infections began when the first hospitalwide outbreak occurred in New York city in 1991 ([@B3]). Since then, reports of CRAB have been accumulating from other parts of the world ([@B4]), including India ([@B5]). Currently, the spread in hospital populations of resistant microorganisms is of great concern worldwide, suggesting that we may be approaching the post-antimicrobial era ([@B6]). This study was undertaken to assess resistance to carbapenem in clinical isolates of *Acinetobacter* spp. from hospitalized patients by both disc-diffusion and minimum inhibitory concentration (MIC) methods.

MATERIALS AND METHODS {#sec1_2}
=====================

Duration and place of study {#sec1_2_1}
---------------------------

A three-year study (2003--2006) was conducted to determine the susceptibility of nosocomial isolates of *Acinetobacter* spp. to different antimicrobials, including imipenem and meropenem. Various specimens were collected from patients admitted to different wards and intensive care unit of S.S. Hospital, Banaras Hindu University, Varanasi, India.

Identification of *Acinetobacter* spp. {#sec1_2_2}
--------------------------------------

Isolation of A*cinetobacter* spp. was done. Briefly, all clinical specimens were initially processed to separate the oxidase-negative, non-fermenters from other gram-negative bacilli. Thereafter, identification was done to confirm *Acinetobacter* spp. by standard protocol ([@B7]).

### In vitro susceptibility {#sec1_2_2_1}

Susceptibility to various antimicrobial agents was determined by the disc-diffusion method and MIC by the agar dilution method following the guidelines of Clinical and Laboratory Standards Institute (CLSI). Antimicrobial susceptibility testing was performed on Mueller Hinton agar by the disc-diffusion method for the following antimicrobial agents (Hi-Media, Mumbai, India) with their concentration given in parentheses: cefotaxime (30 μg), ceftazidime (30 μg), cefoperazone (75 μg), ciprofloxacin (05 μg), norfloxacin (10 μg), amikacin (30 μg), gentamicin (10 μg), tobramycin (10 μg), netilmicin (30 μg), piperacillin (100 μg), carbenicillin (100 μg), cefoperazone/sulbactam (75 μg/30 μg), meropenem (10 μg), and imipenem (10 μg) by the Kirby-Bauer method. Further *in vitro* susceptibility was determined for meropenem (AstraZeneca, India) by MIC with the agar dilution method, and results were interpreted according to the guidelines of CLSI (≤4 μg/mL=sensitive, 8 μg/mL=Intermediate, and ≥16 μg/mL=resistant). Quality control of susceptibility testing was done using ATCC 27853 *Pseudomonas aeruginosa*.

RESULTS {#sec1_3}
=======

In total, 265 *Acinetobacter* spp. were isolated from 1,242 culture-positive samples from hospitalized patients and were identified up to species level as *A.* *baumannii* (91%) and *A. Iwoffii* (9%). On performing disc-diffusion for antimicrobial susceptibility, *Acinetobacter* spp. showed more than 80% resistance to third-generation cephalosporins. Among quinolones, 81% of the isolates were resistant to ciprofloxacin, while norfloxacin was inactive in 78% cases of nosocomial urinary tract infection (UTI) caused by *Acinetobacter* spp. Among aminoglycosides, although amikacin was relatively effective, still 74% of *Acinetobacter* spp. showed resistance to it. Cefoperazone/sulbactam combination was effective with an overall resistance of 31% while 98% of *Acinetobacter* spp. were resistant to piperacillin. Among carbapenems, 9.1% of the isolates were resistant to imipenem and 9.8% to meropenem (Table [1](#T1){ref-type="table"}).

###### 

Antibiotic resistance pattern of *Acinetobacter* species isolated from different wards, expressed in percentage (%)

  Antibiotic                  Post-operative and others (n=154)   ICU (n=89)   Burns (n=22)   Overall (n=265)
  --------------------------- ----------------------------------- ------------ -------------- -----------------
  ß-lactams                                                                                   
   Piperacillin               97.9                                97.4         100.0          97.9
   Carbenicillin              69.6                                71.4         50.0           68.8
   Cefotaxime                 79.0                                83.5         83.3           80.8
   Ceftazidime                77.6                                83.5         83.3           80.0
   Cefoperazone               79.0                                87.3         77.8           82.3
   Imipenem                   07.1                                12.3         09.1           09.1
   Meropenem                  07.7                                12.7         11.1           09.8
  Aminoglycosides                                                                             
   Gentamicin                 83.9                                87.3         94.4           85.8
   Tobramycin                 82.5                                86.0         88.9           84.2
   Amikacin                   74.8                                73.4         77.8           74.6
   Netilmicin                 78.3                                83.5         83.3           80.4
  Quinolones                                                                                  
   Ciprofloxacin              79.7                                83.5         77.8           80.8
   Norfloxacin                78.3                                71.4         100.0          78.1
  Others                                                                                      
   Cefoperazone + sulbactam   27.8                                45.6         27.8           31.2

ICU=Intensive care unit

On performing MIC, 39 isolates of *Acinetobacter* spp., which were resistant to meropenem, showed 6.4% and 8.3% of absolute and intermediate resistance respectively. These 39 isolates were recovered from 34 patients whose clinical data revealed that most of these isolates were from patients admitted to intensive care units (Table [2](#T2){ref-type="table"}). On further analysis, it was observed that 44.9% of the isolates were on borderline to the moderate/resistance range ([Fig.](#F1){ref-type="fig"}). Interestingly, all carbapenem-resistant/intermediate strains of *Acinetobacter* spp. were also resistant to 12 other antibiotics tested by the disc-diffusion method.

![Response of *Acinetobacter* spp. to various concentration ranges of meropenem by MIC](jhpn0026-0183_f01){#F1}

###### 

Clinical data of patients producing carbapenem-resistant Acinetobacters

  Sl. no.   Sample     Ward/ICU   Age (years)   Sex   Clinical diagnosis
  --------- ---------- ---------- ------------- ----- --------------------------
  1         Pus        FSW        45            F     Gall bladder perforation
  2         Pus        MSW        34            M     Non-healing ulcer
  3         Pus        MSW        33            F     Polytrauma
  4         Pus        Spl        50            M     Diabetic foot
  5         Blood      NICU       1             M     Neonatal septicaemia
  6         Pus        Tr         32            M     Crush injury
  7         Pus        Ortho      7             F     Abscess Rt knee
  8         Pus        MSW        33            M     Non-healing ulcer
  9         Pus        Gyn        28            F     PO infection
  10        Swab       ICU        26            M     Multiple fracture
  11        ETT        ICU        50            F     Renal failure
  12        ETT        ICU        61            M     ARDS, with PUO
  13        ETT        ICU        21            F     Respiratory failure
  14        Urine      NICU       12 days       M     UTI
  15        ETT        ICU        35            M     COPD
  16        Pus        MSW        55            M     Necrotizing fascitis
  17        Pus        ICU        45            M     Road traffic accident
  18        Pus        FSW        35            M     Abdominal surgery
  19        Pus        MSW        41            M     Laparotomy
  20        Pus        Burns      70            M     90% burn
  21        Pus        NICU       1 month       M     Cellulitis
  22        ETT        ICU        10            F     Head injury
  23        ETT        ICU        35            M     Bronchial asthma
  24        Tr. tube   ICU        30            M     Pneumonia
  25        Pus        CTVS       45            M     Infective endocarditis
  26        Pus        Burns      30            F     70% burn
  27        Urine      Gyn        22            F     PO infection
  28        ETT        ICU        32            M     COPD, complications
  29        Pus        MSW        44            M     Abdominal surgery
  30        Tr. tube   ICU        43            F     Bronchial asthma
  31        ETT        ICU        70            M     Pneumonia
  32        Pus        Spl        48            M     Bracheal artey injury
  33        Urine      ICU        29            M     Laparatomy
  34        Pus        Surg       27            F     Deglobing injury scalp
  35        Cat. tip   ICU        48            F     Opium poisoning
  36        ETT        ICU        35            F     GI bleeding, pneumonia
  37        Swab       ICU        22            M     Renal failure
  38        ETT        ICU        43            F     Pneumonia
  39        Blood      ICU        47            M     Septicaemia

ARDS=Acute respiratory distress syndrome; Cat=Catheter; COPD=Chronic obstructive pulmonary disease; CTVS=Cardiovascular thoracic surgery; ETT=Endotracheal tube; FSW=Female surgical ward; GI=Gastrointestinal; Gyn=Gynaecology; ICU=Intensive care unit; MSW=Male surgical ward, NICU=Neonatal ICU, PO=Postoperative; Ortho=Orthopaedics; PUO =Pyrexia of unknown origin; Spl =Special ward; Tr=Tracheostomy; UTI=Urinary tract infection

DISCUSSION {#sec1_4}
==========

In the present study, an overall 18% isolation of *Acinetobacter* species in nosocomial colonization/infections was observed. *Acinetobacter* species accounted for 1.4% of all nosocomial infections during 1971--1981 in a university hospital in the United States ([@B8]). A more recent study in a university hospital found that hospitalization in an intensive care unit and previous administration of antibiotics were associated with *Acinetobacter* colonization at various sites of the body in 3.2--10.8 per 1,000 patients ([@B9]). Contrary to the previous studies, a higher prevalence of *Acinetobacter* spp. in the region could be due to lack of good infection-control practices, personal hygiene, over-crowding situations in infirmary, and heavy patient load.

In this study, more than 75% of the isolates were resistant to third-generation cephalosporins, aminoglycosides, and quinolones. Other studies on Acinetobacters have depicted similar results with respect to these antibiotics ([@B10]-[@B13]). Thirty-one percent of these isolates was resistant to cefoperazone-sulbactam; the efficacy of this drug was significant (p\<0.001) compared to other groups of antimicrobials. However, another study showed 46% resistance to cefoperazone-sulbactam by the disc-diffusion method ([@B11]).

Resistance to meropenem was observed in 9.8% of *Acinetobacter* spp. by the disc-diffusion met-hod while 6.4% and 8.3% of the isolates were resistant and intermediate respectively by MIC. Till date, there are limited reports from India on resistance to carbapenem, confirmed by MIC, in the nosocomial isolates of *Acinetobacter* species ([@B5],[@B14]). Taneja *et al.* reported a high incidence (\>20%) of resistance to carbapenem among Acinetobacters in India. However, a report from France showed that 17% of *Acinetobacter* spp. was resistant to meropenem by the agar dilution method while a study in the UK reported 10% resistance which is quite similar to our results ([@B15],[@B16]).

Other studies have shown a high incidence of resistance to carbapenem among Acinetobacters from patients in intensive care units, suggesting that intensive care units are the epicentre for carbapenem-resistant Acinetobacters ([@B17],[@B18]).

Meropenem-resistant *Acinetobacter* spp. was also found to be resistant to all other antimicrobials (Pandrug-resistant *Acinetobacter baumannii*) ([@B19]). This disturbing situation could be attributed to the increased use of antibiotics which has to be controlled by a strict policy for use of antibiotics, in the face of aggressive marketing by the pharmaceuticals. Effective strategies, such as strict infection-control measures, judicious prescriptions of antibiotics, antimicrobial resistance surveillance programmes, and antibiotic cycling have all been tried successfully to control drug resistance in some countries ([@B20]).

Carbapenems have become the drugs of choice in *Acinetobacter-*associated infections in many centres but are slowly being compromised by the emergence of carbapenem-hydrolyzing-lactamases of molecular class B and D ([@B19]). Class B carbapenemases found so far in *Acinetobacter*s include various IMP and VIM types; class D enzymes include members of the OXA-23- and OXA-24-related families and various unsequenced types ([@B20]). Loss of porins, PBP with reduced affinity, efflux pump, AmpC, and different class B and D ß-lactamases have been associated with resistance to carbapenems in clinical strains of *Acinetobacter* spp. ([@B21],[@B22]). A report from India on mechanisms of carbapenem resistance (phenotypic method) among Acinetobacters has suggested that AmpC is responsible for such resistance ([@B5]).

Despite the low prevalence of carbapenem resistance in this study, caution has to be exercised in its use in critically-ill hospitalized patients to check any further increase in the resistance to carbapenems. It is notable that almost 45% isolates of *Acinetobacter* species were on the borderline to moderate/resistant range to carbapenem. Regular monitoring and documentation of carbapenem resistance is, therefore, crucial while developing strategies to control infections due to *Acinetobacter* spp. in hospitalized patients.
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